Bristol-Myers Squibb outlines $46B-$47.5B 2026 revenue target as growth portfolio nears 60% of sales, driven by new product launches and pipeline catalysts
Source: SeekingAlpha
2026-02-05 18:05:01 ET
More on Bristol-Myers Squibb Company
- Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript
- Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)
- Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
- Launch of TrumpRx website set
- Bristol-Myers posts Q4 beat as growth portfolio offsets legacy headwinds
Read the full article on Seeking Alpha
For further details see:
Bristol-Myers Squibb outlines $46B–$47.5B 2026 revenue target as growth portfolio nears 60% of sales, driven by new product launches and pipeline catalysts
Bristol-Myers Squibb $2Pr
NASDAQ: BMYMP
BMYMP Trading
0.0% G/L:
$1050 Last:
5 Volume:
$1050 Open:
BMYMP Latest News
BMYMP Stock Data
$123,712,711,451
2,034,328,000
N/A
1394
N/A
Pharmaceuticals
Healthcare
US
Princeton
